Jaguar Health (JAGX, Financial) is making headlines as First Berlin has initiated coverage on the stock with a "Buy" rating. This announcement was made by analyst Christian Orquera on May 19, 2025.
According to First Berlin, the price target for Jaguar Health (JAGX, Financial) has been set at $60.00 USD. This marks the first time this analyst has rated the stock, as there is no prior rating or price target to compare against.
Investors should take note of this development, as the new coverage and "Buy" rating could influence trading activity and investor sentiment regarding Jaguar Health (JAGX, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Jaguar Health Inc (JAGX, Financial) is $16.00 with a high estimate of $16.00 and a low estimate of $16.00. The average target implies an upside of 167.11% from the current price of $5.99. More detailed estimate data can be found on the Jaguar Health Inc (JAGX) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Jaguar Health Inc's (JAGX, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Jaguar Health Inc (JAGX, Financial) in one year is $4.22, suggesting a downside of 29.55% from the current price of $5.99. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Jaguar Health Inc (JAGX) Summary page.
